Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates.

Encore Dermatology, Inc. is a privately held company headquartered in Malvern, Pennsylvania. Encore Dermatology is committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients. Encore brings together the former leadership team of Precision Dermatology, which was sold to Valeant in 2014. William Crouse is Chairman; Bob Moccia - President and CEO; Rick Havens - Executive Vice President, Sales and Marketing; Boris Meyerson, Ph.D. - Executive Vice President, Business Operations; Kent Taylor - Vice President, Marketing; and Tim Waite - Vice President, Sales. Additionally, Charles W. Stiefel, the former Chairman and CEO of Stiefel Laboratories, has agreed to join the board of directors of Encore.

Bob Moccia states: “We are very excited about this new opportunity to launch a company which understands what dermatologists have always told us; they want effective and safe products and services from companies and people they know and trust.”

Encore will have a wide range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis. The company says it is rapidly expanding through acquisitions, in-licensing, and co-marketing opportunities.